These trials confirmed clinically major pharmacokinetic interactions [7] characterised by a reduce in the clearance with the anticancer drug and as a result amplified exposure. The interpretation of subsequent period II and III clinical trials was complex as it was not possible to administer exactly the same dose of chemotherapy https://atecau099frb1.blogdeazar.com/profile